Heart protected by RASI

Heart Health Harmony: How Renin-Angiotensin System Inhibitors Can Extend Your Life After a Heart Attack

Author's portrait.
Kai Mendoza in Health & Wellness April 2025 • 4 min read.

"Discover the power of RASI therapy post-myocardial infarction. Is it the key to longevity, and how does it compare for STEMI and NSTEMI patients?"


Every year, millions worldwide face the life-altering reality of a heart attack, also known as a myocardial infarction (MI). Modern medicine has made significant strides in treating acute events, but what happens after the initial crisis? How can individuals optimize their long-term health and well-being? Current guidelines emphasize the importance of secondary prevention, with renin-angiotensin system inhibitors (RASI) playing a key role.

RASIs, including ACE inhibitors and angiotensin receptor blockers (ARBs), are medications that help regulate blood pressure and protect the heart. Research suggests they can improve outcomes after a heart attack, but the specifics can be complex. For instance, heart attacks are broadly categorized into two types: ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI).

A recent study has shed light on how RASI therapy impacts long-term survival in patients who have undergone successful percutaneous coronary intervention (PCI) with drug-eluting stents (DES) following a heart attack, focusing on the comparative benefits between STEMI and NSTEMI patients. Let's unpack these findings and explore what they mean for your heart health.

Unlocking the Power of RASI: STEMI vs. NSTEMI

Heart protected by RASI

The study, drawing data from the Korean Acute Myocardial Infarction Registry (KAMIR), involved a large cohort of 24,960 patients who experienced a heart attack and underwent PCI with DES. Researchers compared the impact of RASI therapy on major adverse cardiac events (MACE), all-cause death, cardiac death, and recurrent myocardial infarction over a 2-year period.

One of the most striking findings was that the mortality reduction capability of RASI was more prominent in STEMI patients compared to NSTEMI patients. While RASI therapy showed benefits in both groups, STEMI patients appeared to derive a greater survival advantage. This suggests that the underlying mechanisms and responses to RASI may differ between the two types of heart attacks.
While the study highlights some significant differences, it's important to note that the impact of RASI on other key outcomes was similar between the two groups:
  • Major Adverse Cardiac Events (MACE)
  • Re-Myocardial Infarction (re-MI)
  • Total Revascularization
  • Target Lesion Revascularization (TLR)
Additionally, the study identified several independent risk factors for all-cause death and cardiac death, including older age, decreased left ventricular ejection fraction, hypertension, cardiogenic shock, cardiopulmonary resuscitation on admission, and undergoing PCI within 24 hours of admission. These factors underscore the importance of a holistic approach to heart health management, addressing multiple risk factors to optimize patient outcomes.

The Takeaway: RASI and Your Heart

This study adds to the growing body of evidence supporting the use of RASI therapy after a heart attack. While more research is needed to fully understand the nuances of treatment strategies, the findings suggest that RASI therapy can be particularly beneficial for STEMI patients. If you or a loved one has experienced a heart attack, discussing RASI therapy with your healthcare provider is essential. By working together, you can develop a personalized treatment plan to optimize your long-term heart health and overall well-being.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.